Daiwa Securities Group Inc. - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.

Quarter-by-quarter ownership
Daiwa Securities Group Inc. ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$50.0%6920.0%0.00%
Q2 2023$5
-16.7%
6920.0%0.00%
Q1 2023$6
-25.0%
6920.0%0.00%
Q4 2022$8
-99.9%
6920.0%0.00%
Q3 2022$9,000
+28.6%
6920.0%0.00%
Q2 2022$7,000
-22.2%
692
+31.8%
0.00%
Q1 2022$9,000
+28.6%
5250.0%0.00%
Q4 2021$7,000
-22.2%
525
-14.4%
0.00%
Q3 2021$9,000
+80.0%
613
+84.6%
0.00%
Q2 2021$5,000
+66.7%
3320.0%0.00%
Q1 2021$3,000
+50.0%
3320.0%0.00%
Q4 2020$2,000
-33.3%
332
-66.3%
0.00%
Q3 2020$3,000
+50.0%
986
+13.5%
0.00%
Q2 2020$2,0000.0%8690.0%0.00%
Q1 2020$2,000
-33.3%
8690.0%0.00%
Q4 2019$3,000
+50.0%
869
+24.7%
0.00%
Q3 2019$2,000
-33.3%
6970.0%0.00%
Q2 2019$3,000
-50.0%
6970.0%0.00%
Q1 2019$6,000
+50.0%
697
+28.1%
0.00%
Q4 2018$4,0000.0%5440.0%0.00%
Q3 2018$4,000
+33.3%
5440.0%0.00%
Q2 2018$3,0000.0%5440.0%0.00%
Q1 2018$3,0005440.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q4 2022
NameSharesValueWeighting ↓
VHCP Management, LLC 1,744,356$18,455,0009.59%
RA Capital Management 4,347,456$45,996,0003.30%
Cormorant Asset Management, LP 1,168,000$12,357,0002.84%
Baker Brothers Advisors 5,867,031$62,073,0000.79%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 907,920$9,606,0000.39%
QVT Financial LP 525,734$5,562,0000.32%
EAM Investors, LLC 114,548$1,212,0000.22%
FRANKLIN STREET ADVISORS INC /NC 93,000$984,0000.20%
THB ASSET MANAGEMENT 301,529$3,190,0000.19%
TPG Group Holdings (SBS) Advisors, Inc. 1,162,269$12,297,0000.13%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders